PSTV logo

Plus Therapeutics (PSTV) Company Overview

Profile

Full Name:

Plus Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 11, 2001

Indexes:

Not included

Description:

Plus Therapeutics (PSTV) is a biotechnology company focused on developing innovative treatments for cancer. They specialize in targeted therapies, particularly using radioisotopes to deliver radiation directly to tumors, aiming to improve patient outcomes and reduce side effects compared to traditional cancer treatments.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Jul 22, 2021

Recent annual earnings:

Mar 23, 2017
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

May 1, 2023

Analyst ratings

Recent major analysts updates

Dec 9, 24 Ascendiant Capital
Buy
Nov 26, 24 HC Wainwright & Co.
Buy
Nov 15, 24 HC Wainwright & Co.
Buy
Aug 16, 24 HC Wainwright & Co.
Buy
Aug 15, 23 HC Wainwright & Co.
Buy
Aug 14, 23 HC Wainwright & Co.
Buy
Jun 30, 23 HC Wainwright & Co.
Buy
May 3, 23 Maxim Group
Buy
Apr 21, 23 HC Wainwright & Co.
Buy
Feb 27, 23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Plus Therapeutics?
  • Does Plus Therapeutics pay dividends?
  • What sector is Plus Therapeutics in?
  • What industry is Plus Therapeutics in?
  • What country is Plus Therapeutics based in?
  • When did Plus Therapeutics go public?
  • Is Plus Therapeutics in the S&P 500?
  • Is Plus Therapeutics in the NASDAQ 100?
  • Is Plus Therapeutics in the Dow Jones?
  • When was Plus Therapeutics's last earnings report?
  • When does Plus Therapeutics report earnings?
  • Should I buy Plus Therapeutics stock now?

What is the ticker symbol for Plus Therapeutics?

The ticker symbol for Plus Therapeutics is NASDAQ:PSTV

Does Plus Therapeutics pay dividends?

No, Plus Therapeutics does not pay dividends

What sector is Plus Therapeutics in?

Plus Therapeutics is in the Healthcare sector

What industry is Plus Therapeutics in?

Plus Therapeutics is in the Biotechnology industry

What country is Plus Therapeutics based in?

Plus Therapeutics is headquartered in United States

When did Plus Therapeutics go public?

Plus Therapeutics's initial public offering (IPO) was on July 11, 2001

Is Plus Therapeutics in the S&P 500?

No, Plus Therapeutics is not included in the S&P 500 index

Is Plus Therapeutics in the NASDAQ 100?

No, Plus Therapeutics is not included in the NASDAQ 100 index

Is Plus Therapeutics in the Dow Jones?

No, Plus Therapeutics is not included in the Dow Jones index

When was Plus Therapeutics's last earnings report?

Plus Therapeutics's most recent earnings report was on Jul 22, 2021

When does Plus Therapeutics report earnings?

The date for Plus Therapeutics's next earnings report has not been announced yet

Should I buy Plus Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions